Related Experiment Video
Updated: Jun 26, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Levosimendan for heart-operated patients: what is the state of the art?
Georgios I Tagarakis1, Nikolaos B Tsilimingas
1Department of Cardiovascular and Thoracic Surgery, University of Thessaly, Larissa, Greece. gtagarakis@hotmail.com
Abstract:
Acute heart failure is a common clinical problem faced in cardiac surgery operating rooms and intensive care units. Levosimendan, an inotropic and vasodilating agent used widely in cases of acute heart failure for "cardiological" patients, has not gained global acceptance in its application for heart-operated ones. Herein, we are presenting a series of studies and patents concerning this medication, which, in general, support the use of levosimendan during and after heart surgery, despite the relatively high cost of administration. However, trials with larger samples of patients have to be performed in order to definitively establish this medication as a routinely administered drug for acute congestive heart failure after heart surgery.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy II: Dilated Cardiomyopathy
